Search research articles
Contact Us
Filters
Showing results (371-380 of 379) with videos related to
Page
of 38
Sort By:
You have reached the last page of results.
This site can display upto 379 results.
The Lancet. Oncology
|
September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 22, 2021
Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future
Sofia Spampinato, Nina B K Jensen, Richard Pötter, et al.
Gynecologie, Obstetrique, Fertilite & Senologie
|
July 19, 2025
[Cervical cancer: Guidelines for clinical practice]
Xavier Carcopino, Lobna Ouldamer, Cyrille Huchon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
The Lancet. Oncology
|
December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
Anne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 12, 2022
Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments
Cyrus Chargari, Christine Haie-Meder, Sophie Espenel, et al.
The British Journal of Radiology
|
September 19, 2018
AGuIX
François Lux, Vu Long Tran, Eloïse Thomas, et al.
Page
of 38
Search research articles
Search
Showing results (371-380 of 379) with videos related to
Sort By:
Page
of 38
You have reached the last page of results.
This site can display upto 379 results.
The Lancet. Oncology
|
September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial
Cathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology
|
July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025
Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
International Journal of Radiation Oncology, Biology, Physics
|
October 22, 2021
Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future
Sofia Spampinato, Nina B K Jensen, Richard Pötter, et al.
Gynecologie, Obstetrique, Fertilite & Senologie
|
July 19, 2025
[Cervical cancer: Guidelines for clinical practice]
Xavier Carcopino, Lobna Ouldamer, Cyrille Huchon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 1, 2026
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer - PORTEC-4a an international, randomised, phase 3 trial
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
The Lancet. Oncology
|
December 25, 2025
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Anne Sophie V M van den Heerik, Nanda Horeweg, Marie A D Haverkort, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 13, 2020
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
Anne Sophie V M van den Heerik, Nanda Horeweg, Remi A Nout, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 12, 2022
Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments
Cyrus Chargari, Christine Haie-Meder, Sophie Espenel, et al.
The British Journal of Radiology
|
September 19, 2018
AGuIX
François Lux, Vu Long Tran, Eloïse Thomas, et al.
Page
of 38